Seagen Inc. (NASDAQ:SGEN – Get Rating) Director Daniel G. Welch sold 544 shares of the company’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $200.00, for a total value of $108,800.00. Following the completion of the sale, the director now owns 12,977 shares of the company’s stock, valued at $2,595,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Seagen Trading Down 0.1 %
Shares of NASDAQ SGEN opened at $200.30 on Friday. Seagen Inc. has a 12-month low of $105.43 and a 12-month high of $202.86. The business’s fifty day simple moving average is $153.97 and its 200-day simple moving average is $140.38.
Seagen (NASDAQ:SGEN – Get Rating) last announced its quarterly earnings data on Wednesday, February 15th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.22. The business had revenue of $528.20 million for the quarter, compared to analysts’ expectations of $479.81 million. Seagen had a negative return on equity of 21.13% and a negative net margin of 31.10%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.95) earnings per share. On average, research analysts forecast that Seagen Inc. will post -2.98 earnings per share for the current fiscal year.
Institutional Trading of Seagen
Wall Street Analyst Weigh In
SGEN has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their price objective on Seagen from $154.00 to $150.00 and set an “overweight” rating for the company in a research report on Monday, February 13th. Royal Bank of Canada increased their price objective on Seagen from $155.00 to $229.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 14th. TheStreet upgraded Seagen from a “d+” rating to a “c-” rating in a research report on Wednesday, February 22nd. Morgan Stanley lowered Seagen from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $173.00 to $229.00 in a research report on Wednesday. Finally, Truist Financial increased their price objective on Seagen from $135.00 to $152.00 in a research report on Friday, February 17th. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $187.29.
Seagen Company Profile
Seagen Inc is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B.
- Get a free copy of the StockNews.com research report on Seagen (SGEN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.